Altamira Therapeutics announces publication of results from Bentrio trial

Altamira Therapeutics announced the publication of the detailed results from the NASAR clinical trial with Bentrio nasal spray in seasonal allergic rhinitis. The peer-reviewed article appeared in Allergy, which is published by the European Academy of Allergy and Clinical Immunology and recognizes as one of the highest-ranking journals in the field of allergology. Bentrio is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites. The NASAR trial enrolled 100 patients during two allergy seasons in Australia who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray, the current standard of care in drug-free SAR management. Study participants self-administered the treatment for two weeks three times per day. The primary efficacy endpoint was the reduction in the mean daily reflective Total Nasal Symptom Score. Bentrio-treated patients achieved a significantly lower rTNSS than the saline group with improvement observed across all individual nasal symptoms. Health-related quality of life, as measured by the Rhinoconjunctivitis Quality of Life Questionnaire, was significantly improved as well. Patients and investigators rated the efficacy of treatment as significantly better with Bentrio compared to saline control. Both treatments showed similarly good safety and tolerability. With Bentrio, fewer patients used relief medication and more enjoyed symptom-free days compared to saline treatment. Bentrio is marketed by Altamira Medica AG, an associate company of Altamira Therapeutics, primarily through distributors. From 2024 onwards, Altamira Medica expects sales to grow significantly, mainly driven by the launch of Bentrio in additional countries. The Company expects to conclude partnering discussions and negotiations for distribution in the US, Europe and other key markets in the course of 2024.